MX9705823A - Agentes de contraste para formacion de imagenes para diagnostico que exhiben una mayor retencion en la sangre. - Google Patents

Agentes de contraste para formacion de imagenes para diagnostico que exhiben una mayor retencion en la sangre.

Info

Publication number
MX9705823A
MX9705823A MX9705823A MX9705823A MX9705823A MX 9705823 A MX9705823 A MX 9705823A MX 9705823 A MX9705823 A MX 9705823A MX 9705823 A MX9705823 A MX 9705823A MX 9705823 A MX9705823 A MX 9705823A
Authority
MX
Mexico
Prior art keywords
diagnostic imaging
contrast agents
blood
moiety
compounds
Prior art date
Application number
MX9705823A
Other languages
English (en)
Other versions
MXPA97005823A (es
Inventor
Thomas J Mcmurry
Hironao Sajiki
Daniel M Scott
Randall B Lauffer
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of MX9705823A publication Critical patent/MX9705823A/es
Publication of MXPA97005823A publication Critical patent/MXPA97005823A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/507—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for determination of haemodynamic parameters, e.g. perfusion CT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

La presente invencion se refiere a agentes de contraste para formacion de imágenes para diagnostico con retencion prolongada en la sangre. En particular, la presente invencion se refiere a nuevos compuestos que se caracterizan por una porcion realzadora de imagen (IEM); una porcion ligadora del plasma de la proteína (PPBM); y una porcion prolongada de la vida media en la sangre (BHEM). La presente invencion se refiere también, a composiciones farmacéuticas que comprenden estos compuestos y a los métodos de uso de los compuestos y composiciones para la prolongacion de la vida media en la sangre y para realzar el contraste en la formacion de imágenes de diagnostico.
MXPA/A/1997/005823A 1995-02-01 1997-07-31 Agentes de contraste para formación de imágenes para diagnóstico que exhiben una mayor retención en la sangre MXPA97005823A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38231795A 1995-02-01 1995-02-01
US08/382,317 1995-02-01
PCT/US1996/000164 WO1996023526A2 (en) 1995-02-01 1996-01-16 Diagnostic imaging contrast agents with extended blood retention

Publications (2)

Publication Number Publication Date
MX9705823A true MX9705823A (es) 1997-11-29
MXPA97005823A MXPA97005823A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
JP2004026793A (ja) 2004-01-29
AU689700B2 (en) 1998-04-02
NO973510L (no) 1997-07-30
NL300253I2 (nl) 2007-04-02
US20020164289A1 (en) 2002-11-07
ZA96417B (en) 1996-08-08
DE69636635D1 (de) 2006-11-30
CN101011586A (zh) 2007-08-08
DE122006000061I1 (de) 2007-02-15
CN100361711C (zh) 2008-01-16
US7011815B2 (en) 2006-03-14
WO1996023526A3 (en) 1996-10-17
IL116847A0 (en) 1996-07-23
US20040208827A1 (en) 2004-10-21
KR100403755B1 (ko) 2004-05-24
DE122006000061I2 (de) 2012-06-21
US20120107249A1 (en) 2012-05-03
IS2505B (is) 2009-04-15
ATE342738T1 (de) 2006-11-15
US7060250B2 (en) 2006-06-13
CN1177806C (zh) 2004-12-01
US20070020185A1 (en) 2007-01-25
HK1078468A1 (en) 2006-03-17
TW319763B (es) 1997-11-11
JP2008189683A (ja) 2008-08-21
ES2274523T3 (es) 2007-05-16
AU4654396A (en) 1996-08-21
EP0806968A2 (en) 1997-11-19
US20030180223A1 (en) 2003-09-25
EP1716871A2 (en) 2006-11-02
NL300253I1 (nl) 2007-03-01
NO973510D0 (no) 1997-07-30
JP2006342181A (ja) 2006-12-21
KR19980701833A (ko) 1998-06-25
HK1002551A1 (en) 1998-09-04
IL116847A (en) 1999-11-30
EP0806968B1 (en) 2006-10-18
EP1716871A3 (en) 2011-04-27
FI973183A (fi) 1997-07-31
US20070020184A1 (en) 2007-01-25
JP4064458B2 (ja) 2008-03-19
US20040202613A1 (en) 2004-10-14
CA2211100C (en) 2007-03-20
MY128089A (en) 2007-01-31
NO326114B1 (no) 2008-09-29
US20070003479A1 (en) 2007-01-04
US6676929B2 (en) 2004-01-13
NO20081355L (no) 1997-07-30
IS4523A (is) 1997-07-14
WO1996023526A2 (en) 1996-08-08
BR9607136A (pt) 1997-11-25
US7229606B2 (en) 2007-06-12
NZ301181A (en) 1999-02-25
FI973183A0 (fi) 1997-07-31
US8394356B2 (en) 2013-03-12
AR006510A1 (es) 1999-09-08
PT806968E (pt) 2007-01-31
CN1616111A (zh) 2005-05-18
DE69636635T2 (de) 2007-10-31
US8017105B2 (en) 2011-09-13
CA2211100A1 (en) 1996-08-08
DK0806968T3 (da) 2007-02-05
CN1172436A (zh) 1998-02-04
JP4950110B2 (ja) 2012-06-13
JPH10513445A (ja) 1998-12-22

Similar Documents

Publication Publication Date Title
WO1996023526A3 (en) Diagnostic imaging contrast agents with extended blood retention
WO1998022136A3 (de) Stabile lyophilisierte pharmazeutische zubereitungen von mono- oder polyklonalen antikörpern
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
PT95256A (pt) Processo para a preparacao de agentes quelantes para complexacao com isotopos radioactivos, dos respectivos complexos metalicos e de meios de diagnostico e composicoes farmaceuticas que os contem
CA2100256A1 (en) A method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion,and the use of said agents for said purpose
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
UA32577C2 (uk) Радіомічена сполука для утворення зображення тромбів при радіонуклідній діагностиці, радіофармацевтичний препарат та радіофармацевтична композиція на їх основі та комплект для приготування радіофармацевтичних препаратів
IL159087A0 (en) Bridged bicyclic compounds and pharmaceutical compositions containing the same
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
WO1997002046A3 (de) Saccharid-konjugate
DE69130071D1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
BR0015939A (pt) Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação
BR0109602A (pt) Glóbulos de liberação controlada contendo estavudina
ATE49970T1 (de) Neue pyrrolo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
BG104017A (en) The use of venous contrast matter for projection mammography
KR940021064A (ko) 프레그네인 유도체의 사용 방법
WO1999054463A3 (en) Human k+ ion channel and therapeutic applications thereof
Vosbeck et al. Proteolytic enzymes of the K-1 strain of Streptomyces griseus obtained from a commercial preparation (Pronase). Effect of pH, metal ions, and amino acids on aminopeptidase activity.
EP0346810A3 (en) Heparin for the treatment of lupus
ES546974A0 (es) Un procedimiento de eliminacion del virus lav.
WO1990003172A3 (en) Bile acids for treatment of viral infections
WO2001029068A3 (en) A eag gene encoding for a potassium channel
RU95101840A (ru) Сложные эфиры циклогексанола и содержащий их фармацевтический препарат
AU7178298A (en) Magnetic resonance blood pool agents
Fishbein The History of al-Tabari

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration